Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin

Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin

Autor Medeiros, Eduardo Alexandrino Servolo de Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Medicine School of São Paulo Clinical Hospital
Resumo Respiratory tract infections have an important clinical and economic impact and they are the most common indication for antibiotic use in outpatient practice. This prospective, multicenter non-controlled trial assessed the efficacy and safety of gatifloxacin in the treatment of community-acquired respiratory tract infections. Patients were treated with a daily oral dose of gatifloxacin 400 mg for 7-14 days. The diagnosis of respiratory infection was made based on the clinical condition and/or radiologic findings. A total of 5,044 adult patients with community-acquired respiratory infections was treated with gatifloxacin in different centers in Brazil between March 1, 2001, and October 31, 2001. Among the 5,044 patients treated, 1,501 patients (29.76%) had community-acquired pneumonia, 756 (14.99%) had acute exacerbation of chronic bronchitis and 2,787 (55.25%) had acute sinusitis. Of the total of patients treated, 3,607 (71.51%) were considered cured, 1,261 (25%) progressed with some clinical improvement, 28 (0.56%) presented a relapse, 56 (1.11%) failed to treatment and 92 (1.82%) were unable to be evaluated. Adverse events were described in 634 (12.57%) patients. The most common adverse events were: nausea (2.24%); dyspepsia (1.86%); diarrhea (0.79%); change in taste (0.46%); insomnia and irritability (0.22%); dizziness (0.77%); headache (0.42%); allergic reaction (0.18%); Central Nervous System alterations - insomnia, agitation, anxiety - (0.46%). This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events.
Palavra-chave Gatifloxacin
community-acquired pneumonia
acute sinusitis
acute exacerbation of chronic bronchitis
treatment of respiratory infections
Idioma Inglês
Data de publicação 2002-08-01
Publicado em Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 6, n. 4, p. 149-156, 2002.
ISSN 1413-8670 (Sherpa/Romeo)
Publicador Brazilian Society of Infectious Diseases
Extensão 149-156
Fonte http://dx.doi.org/10.1590/S1413-86702002000400001
Direito de acesso Acesso aberto Open Access
Tipo Artigo
SciELO S1413-86702002000400001 (estatísticas na SciELO)
Endereço permanente http://repositorio.unifesp.br/handle/11600/1491

Exibir registro completo




Arquivo

Nome: S1413-86702002000400001.pdf
Tamanho: 1.558MB
Formato: PDF
Descrição:
Abrir arquivo

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta